Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name CC-115
Synonyms
Therapy Description

CC-115 binds to and inhibits the activity of DNA-PK and mTOR, which may lead to reduced cell proliferation, block downstream signaling, and induce cell death (PMID: 27235137).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
CC-115 mTOR Inhibitor 51 CC-115 binds to and inhibits the activity of DNA-PK and mTOR, which may lead to reduced cell proliferation, block downstream signaling, and induce cell death (PMID: 27235137, PMID: 31853198).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Ewing sarcoma not applicable CC-115 Phase I Actionable In a Phase I trial, CC-115 treatment was tolerated and demonstrated manageable safety, and resulted in stable disease as the best response in 22.2% (2/9) of Ewing sarcoma patients, and a median progression-free survival of 56 days (PMID: 31853198; NCT01353625). 31853198
Unknown unknown malignant choroid melanoma not applicable CC-115 Case Reports/Case Series Actionable In a Phase I trial, CC-115 treatment led to a partial response in a choroid melanoma patient that lasted for 56 days (PMID: 31853198; NCT01353625). 31853198
Unknown unknown Advanced Solid Tumor not applicable CC-115 Phase I Actionable In a Phase I trial, CC-115 treatment was tolerated and demonstrated manageable safety, and resulted in an overall response rate of 5.1% (n=39; 1 complete response, 1 partial response, 18 stable disease), and a disease control rate of 51.3% in advanced solid tumor patients (PMID: 31853198; NCT01353625). 31853198
Unknown unknown glioblastoma not applicable CC-115 Preclinical - Pdx Actionable In a preclinical study, CC-115 increased survival of patient derived xenograft models of glioblastoma (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1755). detail...
Unknown unknown glioblastoma not applicable CC-115 Phase I Actionable In a Phase I trial, CC-115 treatment was tolerated and demonstrated manageable safety, and resulted in stable disease as the best response in 21.4% (3/14) of glioblastoma patients, and a median progression-free survival of 56.5 days (PMID: 31853198; NCT01353625). 31853198
Unknown unknown CLL/SLL not applicable CC-115 Phase I Actionable In a Phase I trial, CC-115 treatment was tolerated and demonstrated manageable safety, and resulted in a partial response in 37.5% (3/8) and a stable disease in 25% (2/8) of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients, and a median progression-free survival was not evaluable (PMID: 31853198; NCT01353625). 31853198
Unknown unknown head and neck squamous cell carcinoma not applicable CC-115 Phase I Actionable In a Phase I trial, CC-115 treatment was tolerated and demonstrated manageable safety, and resulted in stable disease as the best response in 52.9% (9/17) of head and neck squamous cell carcinoma patients, and a median progression-free survival of 74 days (PMID: 31853198; NCT01353625). 31853198
Unknown unknown endometrial cancer not applicable CC-115 Case Reports/Case Series Actionable In a Phase I trial, an endometrial cancer patient achieved a complete response following treatment with CC-115 and remained tumor-free for over 4 years (PMID: 31853198; NCT01353625). 31853198
Unknown unknown prostate cancer not applicable CC-115 Phase I Actionable In a Phase I trial, CC-115 treatment was tolerated and demonstrated manageable safety, and resulted in stable disease as the best response in 63.6% (7/11) of castration-resistant prostate cancer patients, and a median progression-free survival of 345 days (PMID: 31853198; NCT01353625). 31853198

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02977780 Phase II CC-115 Abemaciclib + Temozolomide Temozolomide Neratinib + Temozolomide INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) Recruiting USA 0
NCT01353625 Phase I CC-115 Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. Completed USA 3


Additional content available in CKB BOOST